{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MOXI&page=11",
    "query": {
      "intervention": "MOXI",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 314,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MOXI&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MOXI&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:27:25.940Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00316459",
      "title": "Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Long QT Syndrome"
      ],
      "interventions": [
        {
          "name": "ERB-041",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2006-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-04-13",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00316459"
    },
    {
      "nct_id": "NCT01475513",
      "title": "Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insulin Sensitivity",
        "Cardiovascular Risk",
        "Perimenopausal Disorder"
      ],
      "interventions": [
        {
          "name": "Ortho Cyclen®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 47,
      "start_date": "2011-11",
      "completion_date": "2014-05-28",
      "has_results": true,
      "last_update_posted_date": "2018-08-08",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01475513"
    },
    {
      "nct_id": "NCT00703313",
      "title": "Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "1.5% levofloxacin ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.5% moxifloxacin hydrochloride ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.3% gatifloxacin ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2008-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-02-06",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703313"
    },
    {
      "nct_id": "NCT01775761",
      "title": "A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "TTR Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Period 1",
          "type": "DRUG"
        },
        {
          "name": "Period 2",
          "type": "DRUG"
        },
        {
          "name": "Period 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-01",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2013-05-21",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01775761"
    },
    {
      "nct_id": "NCT02283788",
      "title": "Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "BIA 2-093",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bial - Portela C S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 67,
      "start_date": "2007-03",
      "completion_date": "2007-06",
      "has_results": true,
      "last_update_posted_date": "2025-04-11",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02283788"
    },
    {
      "nct_id": "NCT02027454",
      "title": "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027454"
    },
    {
      "nct_id": "NCT06310876",
      "title": "A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ABBV-CLS-7262",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calico Life Sciences LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2024-03-14",
      "completion_date": "2024-06-26",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06310876"
    },
    {
      "nct_id": "NCT01702376",
      "title": "This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obstetric Labour, Premature"
      ],
      "interventions": [
        {
          "name": "Retosiban 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Retosiban 800 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2012-10-03",
      "completion_date": "2013-01-14",
      "has_results": false,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01702376"
    },
    {
      "nct_id": "NCT00532610",
      "title": "A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GSK189075",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 78,
      "start_date": "2007-09",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-19",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00532610"
    },
    {
      "nct_id": "NCT01674218",
      "title": "Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "PA-824",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 74,
      "start_date": "2012-09",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2014-11-14",
      "last_synced_at": "2026-11-19T05:27:25.940Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674218"
    }
  ]
}